Clinical trial
AML Therapy With Irradiated Allogeneic Cells
NCT02105116 is registered in ClinicalTrials.gov with Rutgers, The State University of New Jersey as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- AML Therapy With Irradiated Allogeneic Cells
- Lead sponsor
- Rutgers, The State University of New Jersey
- Phase
- Not applicable
- Overall status
- Terminated
- Start date
- February 28, 2014
- Completion date
- December 16, 2015
- Enrollment
- 6 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
adult acute megakaryoblastic leukemia (m7), adult acute minimally differentiated myeloid leukemia (m0), adult acute monoblastic leukemia (m5a), adult acute monocytic leukemia (m5b), adult acute myeloblastic leukemia with maturation (m2), adult acute myeloblastic leukemia without maturation (m1), adult acute myeloid leukemia with 11q23 (mll) abnormalities, adult acute myeloid leukemia with del(5q), adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with t(8;21)(q22;q22), adult acute myelomonocytic leukemia (m4), adult erythroleukemia (m6a), adult pure erythroid leukemia (m6b), recurrent adult acute myeloid leukemia, untreated adult acute myeloid leukemia